HEC 921
Alternative Names: HEC-921Latest Information Update: 17 Jul 2026
At a glance
- Originator HEC Pharm
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 22 Apr 2026 Adverse events data from a preclinical trial in Cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 25 Apr 2025 Preclinical trials in Colorectal cancer in China (Parenteral)
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in colorectal cancer presented at the 116th Annual Meeting of the American Association for Cancer Research